NCT00854152

A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

An Open-label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors and Non-Hodgkin's Lymphoma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 121 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with incurable, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen or for which there is no standard therapy.

Conditions

• Non-Hodgkin's Lymphoma, Solid Cancers

Interventions

Type	Name	Description
DRUG	GDC-0980	Escalating repeating dose

Timeline

• Start date: 2009-03-01
• Primary completion: 2014-11-01
• Completion: 2014-11-01
• First posted: 2009-03-03
• Last updated: 2016-11-02

Locations

5 sites across 2 countries: United States, United Kingdom